Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2017 Net Income-$11.92M-$11.92MN/M vs Q3 2017 EPS Diluted-$0.54-$0.54N/M vs Q3 2017 Operating Income-$12,243,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,603,000N/M ended Sep 30, 2018 · filed Nov 8, 2018 · 39 d after period end